- Home
- MAIA vs MRNS Comparison
MAIA vs MRNS Comparison
Compare MAIA & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- MRNS
- Stock Information
- Founded
- MAIA 2018
- MRNS 2003
- Country
- MAIA United States
- MRNS United States
- Employees
- MAIA N/A
- MRNS N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- MRNS Health Care
- Exchange
- MAIA Nasdaq
- MRNS Nasdaq
- Market Cap
- MAIA 62.4M
- MRNS 104.7M
- IPO Year
- MAIA 2022
- MRNS 2014
- Fundamental
- Price
- MAIA $2.82
- MRNS $0.31
- Analyst Decision
- MAIA
- MRNS Buy
- Analyst Count
- MAIA 0
- MRNS 12
- Target Price
- MAIA N/A
- MRNS $4.56
- AVG Volume (30 Days)
- MAIA 60.0K
- MRNS 5.7M
- Earning Date
- MAIA 11-05-2024
- MRNS 11-05-2024
- Dividend Yield
- MAIA N/A
- MRNS N/A
- EPS Growth
- MAIA N/A
- MRNS N/A
- EPS
- MAIA N/A
- MRNS N/A
- Revenue
- MAIA N/A
- MRNS $30,263,000.00
- Revenue This Year
- MAIA N/A
- MRNS $21.18
- Revenue Next Year
- MAIA N/A
- MRNS $56.42
- P/E Ratio
- MAIA N/A
- MRNS N/A
- Revenue Growth
- MAIA N/A
- MRNS 16.56
- 52 Week Low
- MAIA $0.82
- MRNS $0.26
- 52 Week High
- MAIA $5.99
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- MRNS 21.75
- Support Level
- MAIA $2.36
- MRNS $0.29
- Resistance Level
- MAIA $2.72
- MRNS $1.96
- Average True Range (ATR)
- MAIA 0.22
- MRNS 0.12
- MACD
- MAIA 0.02
- MRNS -0.18
- Stochastic Oscillator
- MAIA 72.28
- MRNS 2.41
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.